The United Kingdom government stands at a critical juncture, with a six-month window to determine the fate of a substantial £400 million contract between the National Health Service (NHS) and the American software company Palantir. The core of the debate centers on the effectiveness, necessity, and ethical implications of Palantir’s Federated Data Platform (FDP), a system designed to centralize and organize the vast and often fragmented health data generated across the nation. As political pressure mounts and a significant portion of the NHS grapples with the implementation, questions are being raised by parliamentarians and healthcare professionals alike: if one major region of the NHS can operate successfully without the full adoption of Palantir’s technology, why should the rest of the country be beholden to it?
This complex situation is unfolding against a backdrop of global concerns regarding data privacy, national security, and the increasing reliance on foreign technology in critical public services. The NHS, a cornerstone of British society, is currently navigating a delicate balance between leveraging advanced technological solutions to improve patient care and safeguarding its independence and public trust.
The Genesis of the Federated Data Platform (FDP)
In 2023, the UK government commissioned Palantir to develop a "federated data platform" (FDP). The ambitious goal was to create a unified system capable of ingesting, organizing, and analyzing the immense volume of health data generated across the UK. This data, often stored in disparate systems, spreadsheets, and even paper records, has historically presented significant challenges for effective patient management, resource allocation, and public health initiatives.
According to statements from Palantir and the NHS, the FDP aims to streamline operations by identifying care deficiencies, optimizing resource allocation, and ultimately improving patient outcomes. The purported benefits include reduced wait times, shorter hospital stays, and more efficient utilization of operating theatres. The platform is designed to create a national pool of health data, facilitating the identification of systemic issues, while also offering local databases for regional analysis and the development of tailored tools for specific needs, such as waitlist management or discharge planning. The underlying technological architecture is intended to allow for seamless transfer and adoption of tools and insights across different regions of the NHS.
Mounting Controversy and International Context
Despite the stated objectives and purported benefits, the Palantir-NHS deal has become a significant point of contention within the UK. This controversy is amplified by Palantir’s concurrent involvement in high-profile and often controversial projects globally. The company’s technology has been deployed in conflict zones, such as in theatres of war, and has played a role in the US administration’s immigration enforcement efforts.
These international engagements have fueled public apprehension and led to a wave of protests, petitions, parliamentary inquiries, and even reported dissent among NHS workers. Critics argue that Palantir’s association with such sensitive and ethically charged applications raises fundamental questions about its suitability for managing the highly personal and sensitive data of NHS patients.
Furthermore, the UK’s reliance on Palantir is being scrutinized within a broader European context. Several European nations, increasingly wary of dependence on American technology and often at odds with the Trump administration’s policies, are actively re-evaluating their relationships with Palantir. This trend is driven by a desire to minimize their dependence on US-made technology and to bolster their own sovereign technological capabilities. Reports indicate that countries like France and Germany are exploring or have opted for alternative domestic or European AI and data solutions, signaling a growing unease with US tech dominance in critical infrastructure.
The Greater Manchester Exception: A Case for Local Autonomy
A significant development in the debate has emerged from Greater Manchester, a region that has repeatedly declined to fully adopt Palantir’s FDP. Instead, the health care board for this area has opted to continue utilizing a homegrown platform, the Analytics and Data Science Platform (ADSP), which has been developed over the past decade.
The Greater Manchester Integrated Care Board (ICB), responsible for planning and commissioning healthcare services for approximately 3 million people, has asserted that it does not require Palantir’s FDP, arguing that its own platform is functionally superior and enjoys greater public trust. Matt Hennessey, Chief Data and Analytics Officer at NHS Greater Manchester, has been a vocal proponent of this stance. He told WIRED that "even a technically strong platform will struggle to realize value if clinicians, data controllers, patients or the public do not trust it." He further stated that fully adopting the FDP "would be a retrograde step" for the region.
The ADSP reportedly incorporates primary care data that is not accessible through Palantir’s platform. Its in-house development also allows for greater flexibility and reconfigurability. Hennessey explained that "Because the ADSP is a collection of technologies, if we found that our data visualization software had become less than best in class, we could swap it out." This adaptability is contrasted with the perceived monolithic nature of the FDP.
Crucially, the ADSP has benefited from years of dedicated effort in fostering deep public trust. Hennessey claims that this trust encourages individuals to volunteer the sensitive health data necessary for the platform to function effectively. This public confidence is presented as a vital component for the success of any large-scale health data initiative, a factor that critics suggest is undermined by the controversies surrounding Palantir.
Timeline of the Palantir NHS Deal and Key Developments
- 2023: The UK government commissions Palantir to develop the Federated Data Platform (FDP) for the NHS.
- Early 2024: The NHS begins the rollout of the FDP across various trusts and integrated care boards (ICBs).
- Ongoing throughout 2024: Protests, petitions, and parliamentary inquiries surrounding the Palantir-NHS deal gain momentum. Palantir’s global activities, including its involvement in conflict zones and immigration enforcement, draw increased scrutiny.
- June [Year]: A bipartisan group of UK politicians publishes a report warning of the "unacceptable point of weakness" represented by the nation’s reliance on Palantir and advocating for the termination of the contract.
- July [Year]: A separate parliamentary committee echoes these concerns, citing testimony from Greater Manchester’s health data officials and recommending the termination of the FDP contract in favor of exploring alternative solutions.
- May [Year]: At a meeting in May 2025, the Greater Manchester ICB concludes that its local ADSP platform is superior to the FDP, citing functionalities that are "two to three years" ahead and expressing concerns about public trust.
- April [Year]: Greater Manchester ICB acknowledges delaying a scheduled review of its FDP decision due to heightened public concerns.
- February [Upcoming Year]: The UK government’s six-month window to decide on terminating the Palantir deal expires, potentially allowing the contract to continue until 2031 if not terminated.
Data and Adoption Figures: A Divided Landscape
Official figures from the Department of Health and Social Care indicate a significant level of FDP adoption within the NHS. As of recent reporting, 139 out of approximately 200 NHS trusts are reportedly "live" with Palantir’s technology. Furthermore, 35 of England’s 36 Integrated Care Boards (ICBs) are actively utilizing the system. A spokesperson for the Department of Health and Social Care stated that "It is clear that thousands more patients are benefitting from the FDP every month."
However, these national figures mask regional variations and pockets of resistance. While the majority of ICBs are engaged with the FDP, Greater Manchester stands as a unique outlier. The region’s care board has consistently and unequivocally refused to adopt Palantir’s platform, preferring its homegrown solution. Reports from within the region suggest that even in trusts where the FDP is technically implemented, its usage may be limited, with some entities not fully integrating all their data into the system. Andy Haywood, Chief Digital and Data Officer at Health Innovation Manchester, claimed that trusts in the area are "not going all in" with the FDP, despite appearing on spreadsheets as users. Palantir, however, disputes this, asserting that trusts in Greater Manchester are indeed using the FDP extensively.
The Political and Ethical Dimensions
The debate over the Palantir-NHS contract is increasingly infused with political and ethical considerations. A bipartisan report published in June warned that the UK’s dependence on Palantir constitutes an "unacceptable point of weakness," granting a single foreign vendor significant leverage over a critical national service. The report strongly advocated for the government to exercise its break clause and actively seek domestic alternatives.
Echoing these sentiments, a separate parliamentary committee in July highlighted the potential for political objections to overshadow a rational assessment of the FDP’s performance and value. MP Layla Moran, chair of the committee, emphasized that "Palantir is evidently not the only show in town," suggesting that alternative solutions exist and should be prioritized.
The political context is further complicated by Palantir co-founder Peter Thiel’s past controversial statements, including remarks suggesting the NHS should be "ripped from the ground and start over." While Palantir insists it is not a political organization and that its mission is to leverage technology for public good, such statements, coupled with a recent "fiery bullet-point manifesto" from CEO Alex Karp that a British MP described as "the ramblings of a supervillain," have fueled public distrust.
Health data researcher Jessica Morley from Yale University’s Digital Ethics Center argues that "The NHS is a values-based organization. Palantir is essentially antithetical to all of those values." This sentiment reflects a broader concern among some about the clash between Palantir’s perceived corporate ethos and the fundamental principles of the NHS.
Arguments for and Against the FDP
Proponents of the FDP, including figures like former NHS England Deputy Director of Data Engineering Tom Bartlett, argue that the FDP’s federated architecture offers unparalleled capabilities for national data integration. Bartlett highlights the platform’s "lift and shift" potential, enabling tools developed in one part of the country to be readily adopted elsewhere, and its capacity to serve as a "surface for artificial intelligence to work across." They contend that the calls to break the contract are based on a narrow view of the FDP’s value, focusing solely on care board analytics and neglecting its potential benefits in hospital settings and direct patient care. They also suggest that political opposition, rather than objective performance, is driving the scrutiny, labeling it an "anti-Palantir campaign."
Critics of the FDP, led by figures like Matt Hennessey of NHS Greater Manchester, argue that the perceived technical superiority of the FDP is overshadowed by a lack of public trust. Hennessey maintains that a technically advanced platform is rendered ineffective if it lacks the confidence of clinicians, data controllers, patients, and the public. He also posits that the ADSP in Greater Manchester offers superior functionality and adaptability in a care board setting, and that its long-standing public trust is a critical asset. They argue that the government should seize the opportunity to terminate the contract, citing the "clear mismatch with UK values" and the potential for domestic alternatives.
Implications for the Future of the NHS
The government’s decision within the next six months will have profound implications for the future of data management within the NHS.
- Technological Progress vs. Public Trust: A decision to terminate the contract could halt the progress made in national data integration, potentially pushing trusts back to less efficient systems and jeopardizing efforts to improve patient care through data-driven insights. Conversely, continuing with the contract despite widespread concerns could erode public trust, a critical element for the long-term success of any health data initiative.
- National Sovereignty and Technological Independence: The debate is intrinsically linked to the broader national conversation about technological sovereignty. An unfavorable decision regarding Palantir could spur greater investment in domestic technological capabilities, fostering innovation and reducing reliance on foreign vendors.
- Financial Repercussions: The £400 million contract represents a significant financial commitment. Terminating it early could involve financial penalties, while continuing it might be seen as a misallocation of resources if the platform fails to deliver on its promises or faces continued public resistance.
- Patient Care: Ultimately, the decision will impact patient care. Proponents argue that the FDP is essential for improving efficiency and outcomes, while critics contend that a trusted, homegrown system like the ADSP, or other yet-to-be-identified alternatives, can achieve these goals without compromising public confidence.
The coming months will be crucial as the UK government weighs the purported operational benefits of Palantir’s FDP against the growing chorus of concerns regarding its cost, ethical implications, and the availability of potentially more trusted and adaptable domestic solutions. The outcome will undoubtedly shape the technological landscape of the NHS for years to come.
